Galyfos George, Sianou Argyri
Division of Vascular Surgery, Department of Propaedeutic Surgery, University of Athens Medical School, Hippocration Hospital, Athens, Greece.
Department of Microbiology, University of Athens Medical School, Areteion Hospital, Athens, Greece.
Vasc Specialist Int. 2017 Sep;33(3):89-92. doi: 10.5758/vsi.2017.33.3.89. Epub 2017 Sep 30.
Cilostazol belongs to the new generation antiplatelet agents that have been introduced and studied regarding a potential role in cardiovascular disease prevention or treatment. Although data on peripheral artery disease are sufficient, and the drug has been recommended as first line treatment for intermittent claudication, it has not been approved nor recommended as far as cerebrovascular events are concerned. However, a great volume of randomized as well as pooled data has been published during the last years. Therefore, this review aims to describe the basic mechanisms of cilostazol's action as well as to present all recent clinical data in order to conclude on whether official guidelines should be extended.
西洛他唑属于新一代抗血小板药物，这类药物已被引入并就其在心血管疾病预防或治疗中的潜在作用进行了研究。尽管关于外周动脉疾病的数据充足，且该药物已被推荐为间歇性跛行的一线治疗药物，但就脑血管事件而言，它尚未获得批准或推荐。然而，在过去几年中已经发表了大量的随机数据以及汇总数据。因此，本综述旨在描述西洛他唑的基本作用机制，并呈现所有最新的临床数据，以便得出是否应扩展官方指南的结论。
